Last reviewed · How we verify
XR-B (SUBLOCADETM)
SUBLOCADE is a monthly subcutaneous injection of buprenorphine that provides sustained opioid agonist therapy for opioid use disorder.
SUBLOCADE is a monthly subcutaneous injection of buprenorphine that provides sustained opioid agonist therapy for opioid use disorder. Used for Opioid use disorder in patients who have achieved and sustained clinical stability on a transmucosal buprenorphine-containing product for a minimum of 7 days.
At a glance
| Generic name | XR-B (SUBLOCADETM) |
|---|---|
| Also known as | SUBLOCADE TM |
| Sponsor | NYU Langone Health |
| Drug class | Opioid agonist (buprenorphine) |
| Target | Mu-opioid receptor (partial agonist) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Addiction Medicine |
| Phase | FDA-approved |
Mechanism of action
SUBLOCADE delivers buprenorphine, a partial mu-opioid receptor agonist, via a subdermal implant that releases the drug over approximately one month. This sustained-release formulation reduces withdrawal symptoms and cravings in patients with opioid use disorder while minimizing the abuse potential associated with daily dosing. The extended-release mechanism improves medication adherence and reduces the burden of daily clinic visits.
Approved indications
- Opioid use disorder in patients who have achieved and sustained clinical stability on a transmucosal buprenorphine-containing product for a minimum of 7 days
Common side effects
- Injection site reactions (pain, erythema, induration)
- Headache
- Constipation
- Nausea
- Hyperhidrosis
- Opioid withdrawal symptoms
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- XR-B (SUBLOCADETM) CI brief — competitive landscape report
- XR-B (SUBLOCADETM) updates RSS · CI watch RSS
- NYU Langone Health portfolio CI